Navigation Links
Breckenridge Pharmaceutical Settles 'Paragraph IV' Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
Date:1/11/2008

BOCA RATON, Fla., Jan. 11 /PRNewswire-FirstCall/ -- Breckenridge Pharmaceutical, Inc. announced today that it settled "Paragraph IV" litigation with Novartis concerning Trileptal(R) and that the U.S. Food and Drug Administration approved Breckenridge's Abbreviated New Drug Application for oxcarbazepine 150mg, 300mg and 600 mg tablets in the United States ("Oxcarbazepine Tablets").

Breckenridge enjoys a shared 180-day exclusivity period and will immediately launch Oxcarbazepine Tablets 150 mg, 300 mg, and 600 mg. Oxcarbazepine Tablets are AB rated to Trileptal(R), a $600 million brand name drug marketed by Novartis Pharmaceuticals Corporation, and are used in treating seizures.

Breckenridge is actively seeking development and marketing alliances with domestic and foreign companies for generic and branded pharmaceuticals.

Breckenridge products are contract manufactured through partnerships with pharmaceutical manufacturers in state-of-the-art facilities throughout the U.S. Breckenridge maintains a stringent Quality Assurance program to ensure a consistent supply of quality pharmaceutical products.

About Breckenridge:

Breckenridge Pharmaceutical, Inc., a privately-held pharmaceutical marketing research and development company founded in 1983, is headquartered in Boca Raton, FL, with offices in Berlin, CT, and Fairfield, NJ. Breckenridge markets over 100 products in many therapeutic categories to over 100 customers in all classes of trade.

Trileptal(R) is a registered trademark of Novartis Pharmaceuticals Corporation


'/>"/>
SOURCE Breckenridge Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Breckenridge Pharmaceutical Signs Long Term Agreement with Helm AG (Hamburg, Germany)
2. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
3. NutraCea Forms Joint Ventures With HerbalScience to Develop Nutraceutical Extracts and Pharmaceutical Chemistries From Stabilized Rice Bran
4. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
5. Patient-Centric Healthcare Study Reveals Key Insights for Pharmaceutical Marketers
6. KV Pharmaceutical Company Announces NYSE Listing Extension
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
8. Pharmaceutical Sales: Best Practices for Pharmaceutical Sales Success
9. NPS Pharmaceuticals to Present at the JPMorgan 26th Annual Healthcare Conference on January 9, 2008
10. Gerresheimer Expands its Pharmaceutical Plastic Operations Into Southern Europe and South America
11. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... TSC Advantage has been ... Risk Management Solution Innovations and Security Solution for Government Innovations. Both gold awards ... and its DHS SAFETY Act-designated enterprise security assessment approach. , The ninth annual ...
(Date:8/23/2017)... ... August 23, 2017 , ... The non-profit ... holding an inaugural State of the Science Symposium in partnership with the Global ... 2017. , This symposium provides a forum for global leaders in human nutrition ...
(Date:8/22/2017)... ... August 22, 2017 , ... The Women’s Choice Award, a ... Migraine Relief with the 2017 Women’s Choice Award. The identification by women of an ... out of 4 migraine sufferers are women. In a survey taken by the Women’s ...
(Date:8/22/2017)... ... August 22, 2017 , ... Western ... spoke at a popular international aesthetics conference for medical professionals about the positive ... patients’ health and his growing practice. , Dr. George K. Ibrahim ...
(Date:8/22/2017)... ... August 22, 2017 , ... Each of the past six years, Lightning Labels has sent ... these labels and stickers, demonstrating the variety and creativity of their designs. Submissions this year ... came in. Now, it's time to announce the winners of the sixth annual Photo Contest, ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... president, effective Aug. 7, 2017. ... other interests and will serve as president emeritus during a ... us in multiple leadership roles since he joined Diplomat with ... has provided decisive, strategic leadership which continues to benefit our ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc (NASDAQ: ... agreements to resolve virtually all known U.S. mesh product ... to resolve the known remaining U.S. claims at reasonable ... beginning in the fourth quarter of 2017 and continuing ... its second quarter 2017 results, the Company intends to ...
(Date:8/4/2017)... 3, 2017  Agragen, LLC, a ... the biopharmaceutical, nutraceutical, and aquacultural feed sectors, announces ... lead drug candidates, AGR131.  This drug is designed ... the blood of patients suffering from inflammatory conditions ... disease. Biological ...
Breaking Medicine Technology: